Ascendis Pharma A/S American Depositary Shares ASND
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Ascendis Pharma A/S American Depositary Shares (ASND)
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
Key Insights
Critical company metrics and information
Latest Closing Price
$145.74Market Cap
$8.72 BillionTotal Outstanding Shares
60.69 Million SharesTotal Employees
1,017Dividend
No dividendIPO Date
January 28, 2015Primary Exchange
NASDAQType
American Depository Receipt CommonHomepage
https://www.ascendispharma.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Recent Headlines From The Web
Latest news, press releases, and media coverage about ASND from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.